No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
DNA Ginkgo Bioworks
- 10.080
- +1.340+15.33%
Close Dec 20 16:00 ET
- 10.060
- -0.020-0.20%
Post 20:01 ET
579.39MMarket Cap-0.78P/E (TTM)
10.534High8.400Low3.32MVolume8.460Open8.740Pre Close33.37MTurnover8.35%Turnover RatioLossP/E (Static)57.48MShares74.00052wk High0.73P/B400.96MFloat Cap5.26052wk Low--Dividend TTM39.78MShs Float634.560Historical High--Div YieldTTM24.41%Amplitude5.260Historical Low10.046Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy
Ginkgo Bioworks, Carnegie Mellon University Secure $9.4 Mln To Build Devices For Disease Treatment
Ginkgo Bioworks Secures $9.4M Partnership With Carnegie Mellon To Develop Implantable Cell-Based Bioelectronic Devices For Treating Endocrine Disorders Under ARPA-H's REACT Program
Express News | Ginkgo Bioworks Awarded $9.4 Million in Partnership With Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under Arpa-H's React Program
Ginkgo Bioworks Awarded $9.4 Million in Partnership With Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program
Ferment Launches $20M Studio Fund to Accelerate Biotech Solutions Across Vital Industries
Heat List
US
Overall
Symbol
Price
% Chg
No Data
